Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026)
Repligen (RGEN) posted quarterly Total Non-Current Liabilities of $821.1 million for Q2 2026, up 14.53% year-over-year from $716.9 million in Q2 2025, and up 1.55% quarter-over-quarter from $808.6 million in Q1 2026.
Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Repligen (RGEN) has reported Total Non-Current Liabilities for 16 consecutive years, with $821.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 14.53% year-over-year to $821.1 million; the TTM figure through Jun 2026 stood at $821.1 million (up 14.53% YoY), while the FY2025 annual figure was $707.7 million, down 3.07% from the prior year.
- Total Non-Current Liabilities grew to $821.1 million in Q2 2026 per RGEN's latest filing, from $808.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $821.1 million in Q2 2026 and bottomed at $170.1 million in Q3 2023.
- Historically, Total Non-Current Liabilities has averaged $525.4 million across 5 years, with a median of $706.1 million in 2024.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slipped 21.54% — and 2024, when it jumped 314.93%.
- Repligen's Total Non-Current Liabilities stood at $216.7 million in 2022, then jumped by 223.67% to $701.4 million in 2023, then rose by 4.1% to $730.2 million in 2024, then decreased by 3.07% to $707.7 million in 2025, then gained by 16.01% to $821.1 million in 2026.
- Business Quant data shows RGEN's Total Non-Current Liabilities at $821.1 million in Q2 2026, $808.6 million in Q1 2026, and $707.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Repligen | 10.25 Bn | 9.24 Bn | 110.04 Mn | 821.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 821.06 Mn |
| Mar 31, 2026 | 808.55 Mn |
| Dec 31, 2025 | 707.74 Mn |
| Sep 30, 2025 | 709.49 Mn |
| Jun 30, 2025 | 716.87 Mn |
| Mar 31, 2025 | 714.66 Mn |
| Dec 31, 2024 | 730.16 Mn |
| Sep 30, 2024 | 705.59 Mn |
| Jun 30, 2024 | 706.76 Mn |
| Mar 31, 2024 | 706.55 Mn |
| Dec 31, 2023 | 701.40 Mn |
| Sep 30, 2023 | 170.05 Mn |
| Jun 30, 2023 | 211.85 Mn |
| Mar 31, 2023 | 204.67 Mn |
| Dec 31, 2022 | 216.70 Mn |
| Sep 30, 2022 | 216.73 Mn |
| Jun 30, 2022 | 216.03 Mn |
| Mar 31, 2022 | 193.09 Mn |
| Dec 31, 2021 | 233.03 Mn |
| Sep 30, 2021 | 176.69 Mn |